About: Adeno-Associated Viruses Serotype 2-Mediated RNA Interference Efficiently Inhibits Rabies Virus Replication In Vitro and In Vivo

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Adeno-Associated Viruses Serotype 2-Mediated RNA Interference Efficiently Inhibits Rabies Virus Replication In Vitro and In Vivo Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Adeno-Associated Viruses Serotype 2-Mediated RNA Interference Efficiently Inhibits Rabies Virus Replication In Vitro and In Vivo
Creator	Gao, Yu-Wei Wang, Hua-Lei Wang, Tie-Cheng Wu, Hong-Xia Xia, Xian-Zhu Yang, Song-Tao Yang, Yu-Jiao Guo, Xiao-Feng Ma, Jin-Zhu Zhao, Yong-Kun
Source	Medline; PMC
abstract	To investigate the potential of adeno-associated viruses serotype 2 (AAV2)-mediated RNA interference (RNAi) as an antiviral agent against rabies, recombinant AAV2 vectors expressing siRNA targeting the nucleoprotein (N) gene of rabies virus (RABV) (rAAV-N796) were constructed and evaluated. When NA cells pretreated with rAAV-N796 were challenged with RABV, there was a 37.8 ± 3.4% to 55.1 ± 5.3% reduction in RABV virus titer. When cells pre-challenged with RABV were treated with rAAV-N796, there was a 4.4 ± 1.4 to 28.8 ± 3.2% reduction in RABV virus titer. Relative quantification of RABV transcripts using real-time PCR and Western blot revealed that the knockdown of RABV-N gene transcripts was based on the rAAV-N796 inoculation titer. When any NA cells were treated with rAAV-N796 before or after challenged with RABV, significant reduction in virus titer was observed in both administrations. Mice treated intracerebrally with rAAV-N796 exhibited 50 ± 5.3 and 62.5 ± 4.7% protection when challenged intracerebrally or intramuscally, respectively, with lethal RABV. When mice treated intramuscularly with rAAV-N796 were challenged intramuscularly with lethal RABV, they exhibited 37.5 ± 3.7% protection. When mice were intracerebrally and intramuscularly with rAAV-N796 24 hr after exposure to RABV infection, they exhibited 25 ± 4.1% protection The N gene mRNA levels in the brains of challenged mice with three different administrations were reduced (55, 68, 32 and 25%, respectively). These results indicated that AAV2 vector-mediated siRNA delivery in vitro in NA cells inhibited RABV multiplication, inhibited RABV multiplication in vivo in the mice brain and imparted partial protection against lethal rabies. So, it may have a potential to be used as an alternative antiviral approach against rabies.
has issue date	2013-06-14(xsd:dateTime)
bibo:doi	10.1292/jvms.13-0127
bibo:pmid	23774028
has license	cc-by-nc-nd
sha1sum (hex)	efd6ea1e3d5223f220c6c09084ac5fb043618b03
schema:url	https://doi.org/10.1292/jvms.13-0127
resource representing a document's title	Adeno-Associated Viruses Serotype 2-Mediated RNA Interference Efficiently Inhibits Rabies Virus Replication In Vitro and In Vivo
has PubMed Central identifier	PMC3942934
has PubMed identifier	23774028
schema:publication	J Vet Med Sci
resource representing a document's body	covid:efd6ea1e3d5223f220c6c09084ac5fb043618b03#body_text
is schema:about of	named entity 'TO INVESTIGATE' named entity 'EXPOSURE TO' named entity 'BRAIN' named entity 'NUCLEOPROTEIN' named entity 'MICE' named entity 'POTENTIAL' named entity '2855' named entity '4.4' named entity '3.4' named entity 'USING' named entity 'BRAINS' named entity '3.2' named entity 'VECTOR' named entity 'TITER' named entity 'CONSTRUCTED' named entity 'MAY HAVE' named entity 'ADENO-ASSOCIATED VIRUSES' named entity 'TARGETING' named entity 'OBSERVED' named entity 'GENE TRANSCRIPTS' named entity 'THESE' named entity 'gene' named entity 'inoculation' named entity 'vectors' named entity 'rabies' named entity 'recombinant' named entity 'reduced' named entity 'partial' named entity 'Vitro' named entity 'RNA INTERFERENCE' named entity 'RELATIVE' named entity 'REDUCED' named entity 'VECTORS' named entity 'WAS A' named entity 'SEROTYPE' named entity 'GENE OF RABIES VIRUS' named entity '4.1' named entity 'VIRUS' named entity 'SIRNA DELIVERY' named entity 'RABIES VIRUS' named entity 'VIRUS REPLICATION' named entity 'MEDIATED' named entity 'IN VITRO' named entity 'ADENO-ASSOCIATED VIRUSES' named entity '62.5' named entity 'INFECTION' named entity 'CELLS' named entity 'IN VIVO' named entity 'ANTIVIRAL AGENT' named entity 'USED' named entity 'RNA INTERFERENCE' named entity 'REDUCTION' named entity 'MRNA' named entity 'MULTIPLICATION' named entity 'RECOMBINANT' named entity 'IN VITRO' named entity 'LEVELS' named entity 'IN VIVO' named entity 'TRANSCRIPTS' named entity 'N GENE' named entity 'RESULTS' named entity 'SIGNIFICANT' named entity 'INHIBITED' named entity 'RABIES' named entity 'INDICATED' named entity 'RABV' named entity 'WESTERN BLOT' named entity 'MEDIATED' named entity '5.3' named entity 'SEROTYPE' named entity 'PARTIAL' named entity 'BASED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software